Veradermics reports positive Phase 2 Study 207 results for VDPHL01 in female hair loss
Veradermics said topline results from its open-label Phase 2 Study 207 showed increases in hair count and patient-reported improvement in women with mild-to-moderate pattern hair loss after six months of oral VDPHL01 treatment. The company said the results support its registration-directed Phase 2/3 Study 306 in women, with topline data expected in the first half of 2027. The filing contains no financial results, and the study was open-label.
Key points
- Study 207 enrolled 28 adult female participants; women on VDPHL01 4.5 mg once daily or twice daily showed mean non-vellus hair count increases of 22.7 and 23.3 hairs/cm² at Month 6.
- 88.9% (once daily) and 90.0% (twice daily) of women rated improved or much improved on the AAIRS at Month 6.
- No treatment-related serious adverse events were reported; the most common adverse events were hypertrichosis and peripheral edema.
- Topline results from Phase 2/3 Study 306 in women are anticipated in the first half of 2027.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 15, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.